Researchers report P-selectin-targeted nanotherapy selectively depletes senescent cells and reverses fibrosis in preclinical models

The development of P-selectin-targeted senescence-modulating nanoparticles demonstrates a highly selective method to deplete pathogenic senescent cells, offering a potential therapeutic avenue to reverse tissue fibrosis and overcome immune exclusion in oncology.

A study published in Science on September 24, 2026, demonstrated that P-selectin is expressed by a specific subset of pathogenic, senescent-like cells in both fibrotic tissues and tumor microenvironments.

The researchers designed fucoidan-based senescence-modulating nanoparticles (SMNPs) that bind to P-selectin, enabling the selective targeting and modulation of these disease-associated senescent states.

In vivo testing showed that SMNPs exerted potent antifibrotic and immunomodulatory effects, specifically targeting and depleting an immunosuppressive macrophage population.

In fibrotic tumor models, this niche remodeling successfully restored immune cell infiltration and sensitized previously resistant tumors to immune checkpoint-based therapies.

While senescent cells are established drivers of age-related fibrosis, their functional heterogeneity has historically complicated efforts to target them without causing off-target toxicity.

By identifying P-selectin as a targetable cell-surface marker for a specific pathogenic senescent subpopulation, the study offers a strategy to improve the therapeutic index of senolytic therapies.

Resolving the immunosuppressive microenvironment of fibrotic tissues could expand the efficacy of existing immunotherapies, which are frequently rendered ineffective by immune exclusion.

This research could accelerate industry shift away from systemic, broad-spectrum small-molecule senolytics toward cell-surface-targeted nanomedicines.

The integration of senotherapeutic targets with oncology and checkpoint inhibitors opens new development pathways for combination regimens in highly fibrotic, treatment-resistant cancers.

Success in targeting P-selectin may lead to increased development and licensing activity surrounding fucoidan-based or selectin-binding nanoparticle platforms.

The advancement of these fucoidan-based SMNPs into IND-enabling studies to evaluate their toxicity, pharmacokinetics, and biodistribution in larger animal models.

Whether clinical trials will focus initially on severe fibrotic conditions, such as idiopathic pulmonary fibrosis, or on immune-excluded solid tumors where checkpoint inhibitors have failed.